Literature DB >> 9398040

Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group.

T R Coté1, R J Biggar, P S Rosenberg, S S Devesa, C Percy, F J Yellin, G Lemp, C Hardy, J J Geodert, W A Blattner.   

Abstract

We describe the anatomic and histologic presentation and prognosis of non-Hodgkin's lymphoma (NHL) among people with AIDS (PWA) and determine their contribution to the NHL burden. We linked AIDS and cancer registries in selected areas of the United States and compared NHL sites and histologies in PWA and non-PWA, after adjusting for age, sex and ethnicity. Among 51,033 PWA, we found 2,156 cases of NHL (4.3%). Half of NHL cases occurring post-AIDS were not reported to AIDS registries. NHL was part of an AIDS-defining condition for 3.2% of all PWA; the relative risk of NHL with 3.5 years of another AIDS diagnosis was 165-fold compared to non-PWA within the cancer surveillance system. Of NHLs, 39% were high grade (vs. 12% among non-PWA), 60% were nodal (vs. 74% among non-PWA) and 15% had brain primaries (vs. 1% among non-PWA). Excluding brain sites, extranodal sites were still 20% more common than expected. Relative risk was elevated for all histologic types, with the risk ranging from 652-fold for high-grade diffuse immunoblastic tumors and 261-fold for Burkitt's lymphomas to 113 for intermediate-grade lymphoma to 14-fold for low-grade lymphoma. Survival among PWA with NHL was poor, and tumor grade had little impact. In high-risk AIDS areas, AIDS-related NHLs constitute a major share of the NHL burden. We conclude that NHL risk is considerably under-estimated in AIDS registry data. The major differences between PWA and non-PWA were the high frequency of brain lymphoma and the increase in high-grade lymphomas in PWA. However, the grade of NHL did not influence the prognosis among PWA with lymphoma. The increasing risk of NHL in PWA has contributed substantially to the general increase in NHL rates in the United States since 1981.

Entities:  

Mesh:

Year:  1997        PMID: 9398040     DOI: 10.1002/(sici)1097-0215(19971127)73:5<645::aid-ijc6>3.0.co;2-x

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  57 in total

1.  Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana.

Authors:  Tanja Mesti; Tanja Južnič Setina; Marjeta Vovk; Barbara Jezeršek Novaković
Journal:  Med Oncol       Date:  2011-04-24       Impact factor: 3.064

Review 2.  Therapy of non-Hodgkin's lymphoma.

Authors:  J Coffey; D C Hodgson; M K Gospodarowicz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

3.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data.

Authors:  Sam M Mbulaiteye; Kishor Bhatia; Clement Adebamowo; Annie J Sasco
Journal:  Infect Agent Cancer       Date:  2011-10-17       Impact factor: 2.965

Review 6.  Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.

Authors:  Stefan K Barta; Xiaonan Xue; Dan Wang; Roni Tamari; Jeannette Y Lee; Nicolas Mounier; Lawrence D Kaplan; Josep-Maria Ribera; Michele Spina; Umberto Tirelli; Rudolf Weiss; Lionel Galicier; Francois Boue; Wyndham H Wilson; Christoph Wyen; Albert Oriol; José-Tomás Navarro; Kieron Dunleavy; Richard F Little; Lee Ratner; Olga Garcia; Mireia Morgades; Scot C Remick; Ariela Noy; Joseph A Sparano
Journal:  Blood       Date:  2013-09-06       Impact factor: 22.113

7.  Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis.

Authors:  Riccardo Dolcetti; Cinzia Giagulli; Wangxiao He; Marina Selleri; Francesca Caccuri; Lindsay M Eyzaguirre; Pietro Mazzuca; Silvia Corbellini; Federica Campilongo; Stefania Marsico; Emanuela Giombini; Elena Muraro; Gabriella Rozera; Paolo De Paoli; Antonino Carbone; Maria Rosaria Capobianchi; Giuseppe Ippolito; Simona Fiorentini; William A Blattner; Wuyuan Lu; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

8.  Impact of infection with human immunodeficiency virus-1 (HIV) on the risk of cancer among children in Malawi - preliminary findings.

Authors:  Nora Mutalima; Elizabeth M Molyneux; William T Johnston; Harold W Jaffe; Steve Kamiza; Eric Borgstein; Nyengo Mkandawire; George N Liomba; Mkume Batumba; Lucy M Carpenter; Robert Newton
Journal:  Infect Agent Cancer       Date:  2010-02-12       Impact factor: 2.965

9.  Lymphoreticular diseases in Nigerians.

Authors:  Kayode A Adelusola; Donatus O Sabageh; Cornelius O Ukah
Journal:  Afr Health Sci       Date:  2008-03       Impact factor: 0.927

10.  Quality of life, characteristics and survival of patients with HIV and lymphoma.

Authors:  Catherine Diamond; Thomas H Taylor; Hoda Anton-Culver
Journal:  Qual Life Res       Date:  2010-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.